Sleep research article
Varivax (<i>Aesculus hippocastanum</i> L.): A dietary supplement with antioxidant and antidepressant potential in adult zebrafish.
Authors: Lima LS , de Oliveira MRC , do Nascimento GA , da Silva JGL , de Sousa DB , Coelho PAT , de Sousa JA , de Oliveira KA , Batista FLA , Ishiki HM , Queiroz EAM , Sobreira VL , da Silva CMM , Frota LS , Barbosa SICG , de Morais SM , da Silva WMB , de Oliveira Pinheiro S , Farias-Pereira R , Santos SAAR , de Sousa Rodrigues ALO , Gois RR , Assis JRR , Vieira-Neto AE , Moura LFWG , Raposo RDS , Campos AR , Magalhães FEA
One-line summary
A sleep science research article on Varivax (<i>Aesculus hippocastanum</i> L.): A dietary supplement with antioxidant and antidepressant potential in adult zebrafish..
Sleep health notes
Sleep health notes will be added by the Sleepatch editorial team.
中文解读
中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。
Original abstract
Varivax (<i>Natulab</i>®) is a dietary supplement composed of dry extract of horse chestnut (<i>Aesculus hippocastanum</i> L.), standardized to 20% anhydrous escin and indicated for chronic venous insufficiency, pain, and leg swelling. In this context, the present study aimed to investigate the antioxidant and antidepressant effects of Varivax (VRX) and its possible neuromodulatory mechanisms. Initially, VRX was subjected to in vitro antioxidant activity assessment using the DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)] assays. For the in vivo assays, to evaluate non-clinical safety, adult zebrafish (aZF; n = 6/group) were treated (20 μL; oral administration) with VRX (0.1, 1.0, or 10 mg/mL), and sedative effects (open field test) and toxicity (96 h) were assessed. To investigate the antidepressant effect, aZF (n = 6/group) were subjected to the Tail Immobilization Test (TIT), and antidepressant-like activity was characterized by an increase in mobility time (s). Subsequently, the possible in vivo modulation of the serotonergic system by VRX was investigated, and in silico molecular docking was performed to evaluate the potential modulation of serotonergic receptors (5-HT<sub>2A</sub>, 5-HT<sub>1</sub>, 5-HT<sub>2A/2C</sub>, and 5-HT<sub>3A/3B</sub>) by escin. Fluoxetine was used as the reference drug for validating the results. As a result, VRX did not exhibit toxic or sedative effects in adult zebrafish and demonstrated antidepressant-like activity involving serotonergic receptors 5-HT<sub>2A</sub>, 5-HT<sub>1</sub>, 5-HT<sub>2A/2C</sub>, and 5-HT<sub>3A/3B</sub>, which were supported by the interaction potential observed in the in silico assays. The results of <i>in vivo</i> and <i>in silico</i> analyses demonstrated that VRX exhibited an antidepressant effect at the highest dose tested, with a response comparable to fluoxetine. The present study highlights the medicinal potential of this supplement in the prospecting of phytopharmaceuticals for depression.
Links and sources
This content is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sleep disorders, chronic insomnia, sleep apnea, and other conditions must be evaluated and treated by a qualified healthcare professional. If you experience persistent or severe sleep problems, consult a licensed physician or sleep specialist. Research cited refers to peer-reviewed studies; individual results may vary. Sleepatch does not endorse any specific medication, supplement, or therapy.
Want a personalized sleep improvement plan?
Sleepatch can prepare a customized sleep wellness program, insomnia relief guide, and evidence-based sleep coaching based on your needs.
Explore sleep services
Comments